Role of endogenous hydrogen sulfide synthesis gene polymorphisms in the long-term prognosis of patients with ischemic cardiomyopathy related chronic heart failure in Chinese Han population

Nitric Oxide ◽  
2015 ◽  
Vol 47 ◽  
pp. S18
Author(s):  
Lan Ren ◽  
Zhouying Liu ◽  
Xuhua Chen ◽  
Xiaoyan Liu ◽  
Jielin Pu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hydrogen Sulfide ◽  
Chronic Heart Failure ◽  
Gene Polymorphisms ◽  
Ischemic Cardiomyopathy ◽  
Chinese Han ◽  
Han Population ◽  
Long Term Prognosis

scholarly journals Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation

2020 ◽  
Vol 27 (2_suppl) ◽  
pp. 27-34
Author(s):  
Stefania Paolillo ◽  
Angela B Scardovi ◽  
Jeness Campodonico
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Atrial Fibrillation ◽  
Chronic Heart Failure ◽  
Iron Deficiency ◽  
Prognostic Impact ◽  
Heart Failure Patients ◽  
Cardiovascular Comorbidities ◽  
Long Term Prognosis

Cardiovascular and non-cardiovascular comorbidities are frequently observed in heart failure patients, complicating the therapeutic management and leading to poor prognosis. The prompt recognition of associated comorbid conditions is of great importance to optimize the clinical management, the follow-up, and the treatment of patients affected by chronic heart failure. Anaemia and iron deficiency are commonly reported in all heart failure forms, have a multifactorial aetiology and are responsible for reduced exercise tolerance, impaired quality of life, and poor long-term prognosis. Diabetes mellitus is highly prevalent in heart failure and a poor glycaemic control is associated with worst outcome. Two specific heart failure forms are usually observed in diabetic patients: an ischaemic cardiomyopathy or a typical diabetic cardiomyopathy. The implementation of use of sodium-glucose cotransporter-2 inhibitors will much improve in the near future the long-term prognosis of patients affected by heart failure and diabetes. Among cardiovascular comorbidities, atrial fibrillation is the most common arrhythmic disease of heart failure patients and it is still not clear whether its presence should be considered as a prognostic indicator or as a marker of advanced disease. The aim of the present review was to explore the clinical and prognostic impact of anaemia and iron deficiency, diabetes mellitus, and atrial fibrillation in patients affected by chronic heart failure.

Long-term prognosis of combined chronic heart failure and chronic renal dysfunction after acute stroke

2010 ◽  
Vol 12 (8) ◽  
pp. 849-854 ◽  
Author(s):  
George Tsagalis ◽  
Neratzoula Bakirtzi ◽  
Konstantinos Spengos ◽  
Anastasia Vemmou ◽  
Efstathios Manios ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Acute Stroke ◽  
Renal Dysfunction ◽  
Long Term Prognosis

scholarly journals Role of endogenous endothelin in a rat model of chronic heart failure: Long-term effects of the endothelin antagonist Bosentan

1996 ◽  
Vol 27 (2) ◽  
pp. 258
Author(s):  
Paul Mulder ◽  
Vincent Richard ◽  
Jean-Paul Henry ◽  
Francoise Lallemand ◽  
Christian Thuillez
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Rat Model ◽  
Long Term Effects ◽  
Endothelin Antagonist

scholarly journals Predictive Value of the Serum Cystatin C/Prealbumin Ratio in Combination With NT-proBNP Levels for Long-Term Prognosis in Chronic Heart Failure Patients: A Retrospective Cohort Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Chuanhe Wang ◽  
Su Han ◽  
Fei Tong ◽  
Ying Li ◽  
Zhichao Li ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cystatin C ◽  
Cardiovascular Mortality ◽  
Retrospective Cohort ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
All Cause Mortality ◽  
Long Term Prognosis

Aim: The present study was established to investigate the use of the serum cystatin C/prealbumin (Cys-C/PAB) ratio as a predictive factor for long-term prognosis in patients with chronic heart failure.Methods: We divided our retrospective cohort of 6,311 patients admitted to hospital due to an episode of heart failure (HF) into three groups according to the Cys-C/PAB ratio. The endpoints were cardiovascular and all-cause mortality. Median follow-up time were 3.3 years (2–8 years), during which 2,945 (46.7%) patients died.Results: The Cys-C/PAB ratio was revealed to be an independent predictor of cardiovascular mortality (HR: 1.12, 95% CI: 1.15–1.23, P < 0.01) and all-cause mortality (HR: 1.19, 95% CI: 1.13–1.24, P < 0.01) by multivariable Cox analysis. Integrated discrimination improvement (IDI) showed that the Cys-C/PAB ratio in conjunction with the level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) conferred a significant improvement in predicting individual risks of cardiovascular (P = 0.023) and all-cause (P = 0.028) mortality. For those with a high Cys-C/PAB ratio in combination with a high NT-proBNP level, the long-term cardiovascular mortality risk ratio was 8.6-times higher than for those with low values, and 7.51-times for all-cause mortality. Our study also showed that Cys-C/PAB and NT-proBNP in combination displayed higher value for the prediction of cardiovascular and all-cause in-hospital mortality in patients with HF.Conclusions: The Cys-C/PAB ratio is valuable for predicting cardiovascular and all-cause mortality in patients with HF and offers additional information to that provided by NT-proBNP.

Sign in / Sign up

Export Citation Format

Share Document